Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies After Infection with Variants of Concern or Vaccination

Overview

Journal Vaccines (Basel)

Date 2021 Jul 2

PMID 34202276

Citations 16

Authors

Franziska Neumann

Ruben Rose

Janine Rompke

Olaf Grobe

Thomas Lorentz

Helmut Fickenscher

Andi Krumbholz

Affiliations

Soon will be listed here.

Abstract

The humoral immunity after SARS-CoV-2 infection or vaccination was examined. Convalescent sera after infection with variants of concern (VOCs: B.1.1.7, = 10; B.1.351, = 1) and sera from 100 vaccinees (Pfizer/BioNTech, BNT162b2, = 33; Moderna, mRNA-1273, = 11; AstraZeneca, ChAdOx1 nCoV-19/AZD1222, = 56) were tested for the presence of immunoglobulin G (IgG) directed against the viral spike (S)-protein, its receptor-binding domain (RBD), the nucleoprotein (N) and for virus-neutralizing antibodies (VNA). For the latter, surrogate assays (sVNT) and a Vero-cell based neutralization test (cVNT) were used. Maturity of IgG was determined by measuring the avidity in an immunoblot (IB). Past VOC infection resulted in a broad reactivity of anti-S IgG (100%), anti-RBD IgG (100%), and anti-N IgG (91%), while latter were absent in 99% of vaccinees. Starting approximately two weeks after the first vaccine dose, anti-S IgG (75-100%) and particularly anti-RBD IgG (98-100%) were detectable. After the second dose, their titers increased and were higher than in the convalescents. The sVNT showed evidence of VNA in 91% of convalescents and in 80-100%/100% after first/second vaccine dose, respectively. After the second dose, an increase in VNA titer and IgGs of high avidity were demonstrated by cVNT and IB, respectively. Re-vaccination contributes to a more robust immune response.

Citing Articles

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.

Wietschel K, Fechtner K, Antileo E, Abdurrahman G, Drechsler C, Makuvise M Front Immunol. 2024; 15:1382911.

PMID: 38807606 PMC: 11130424. DOI: 10.3389/fimmu.2024.1382911.

Performance Analysis of Serodiagnostic Tests to Characterize the Incline and Decline of the Individual Humoral Immune Response in COVID-19 Patients: Impact on Diagnostic Management.

von Possel R, Menge B, Deschermeier C, Fritzsche C, Hemmer C, Geerdes-Fenge H Viruses. 2024; 16(1).

PMID: 38257792 PMC: 10820597. DOI: 10.3390/v16010091.

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.

Kozma G, Meszaros T, Berenyi P, Facsko R, Patko Z, Olah C Vaccine. 2023; 41(31):4561-4570.

PMID: 37330369 PMC: 10239905. DOI: 10.1016/j.vaccine.2023.06.009.

Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy.

Koller A, Szebeni J Hum Vaccin Immunother. 2023; 19(1):2188035.

PMID: 37062957 PMC: 10114996. DOI: 10.1080/21645515.2023.2188035.

Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference.

Graninger M, Jani C, Reuberger E, Pruger K, Gaspar P, Springer D Microbiol Spectr. 2023; 11(1):e0231422.

PMID: 36622205 PMC: 9927416. DOI: 10.1128/spectrum.02314-22.

References

von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T, Rodionov R . Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J Virol Methods. 2020; 288:114031. PMC: 7707675. DOI: 10.1016/j.jviromet.2020.114031. View

Bauer G . The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021; 106:61-64. PMC: 7944804. DOI: 10.1016/j.ijid.2021.01.061. View

Bauer G . The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity). J Med Virol. 2020; 93(1):311-322. PMC: 7361859. DOI: 10.1002/jmv.26262. View

Hu B, Guo H, Zhou P, Shi Z . Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020; 19(3):141-154. PMC: 7537588. DOI: 10.1038/s41579-020-00459-7. View

Iacobucci G . Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show. BMJ. 2021; 373:n1068. DOI: 10.1136/bmj.n1068. View

Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287):1819-1829. PMC: 8099315. DOI: 10.1016/S0140-6736(21)00947-8. View

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

Klasse P, Nixon D, Moore J . Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci Adv. 2021; 7(12). PMC: 7978427. DOI: 10.1126/sciadv.abe8065. View

Stromer A, Rose R, Schafer M, Schon F, Vollersen A, Lorentz T . Performance of a Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms. 2020; 9(1). PMC: 7823488. DOI: 10.3390/microorganisms9010058. View

10.

Bauer G, Struck F, Schreiner P, Staschik E, Soutschek E, Motz M . The challenge of avidity determination in SARS-CoV-2 serology. J Med Virol. 2021; 93(5):3092-3104. PMC: 8013859. DOI: 10.1002/jmv.26863. View

11.

Kyriakidis N, Lopez-Cortes A, Gonzalez E, Grimaldos A, Prado E . SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021; 6(1):28. PMC: 7900244. DOI: 10.1038/s41541-021-00292-w. View

12.

Vasileiou E, Simpson C, Shi T, Kerr S, Agrawal U, Akbari A . Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397(10285):1646-1657. PMC: 8064669. DOI: 10.1016/S0140-6736(21)00677-2. View

13.

Kristiansen P, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K . WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021; 397(10282):1347-1348. PMC: 7987302. DOI: 10.1016/S0140-6736(21)00527-4. View

14.

Embregts C, Verstrepen B, Langermans J, Boszormenyi K, Sikkema R, de Vries R . Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. One Health. 2021; 13:100313. PMC: 8378998. DOI: 10.1016/j.onehlt.2021.100313. View

15.

Creech C, Walker S, Samuels R . SARS-CoV-2 Vaccines. JAMA. 2021; 325(13):1318-1320. DOI: 10.1001/jama.2021.3199. View

16.

Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D . Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021; 384(20):1959-1961. PMC: 8008753. DOI: 10.1056/NEJMc2102051. View

17.

Stromer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T . Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection. Microorganisms. 2020; 8(10). PMC: 7650537. DOI: 10.3390/microorganisms8101572. View

18.

Meyer B, Reimerink J, Torriani G, Brouwer F, Godeke G, Yerly S . Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg Microbes Infect. 2020; 9(1):2394-2403. PMC: 7605318. DOI: 10.1080/22221751.2020.1835448. View

19.

Li M, Lou F, Fan H . SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency. Signal Transduct Target Ther. 2021; 6(1):151. PMC: 8035603. DOI: 10.1038/s41392-021-00592-6. View

20.

Emary K, Golubchik T, Aley P, Ariani C, Angus B, Bibi S . Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021; 397(10282):1351-1362. PMC: 8009612. DOI: 10.1016/S0140-6736(21)00628-0. View